Literature DB >> 30904732

Systemic response of coated-platelet and peripheral blood inflammatory cell indices after aneurysmal subarachnoid hemorrhage and long-term clinical outcome.

Bappaditya Ray1, Stephen R Ross2, Gopichand Danala3, Faranak Aghaei3, Claire Delpirou Nouh2, Lance Ford4, Kimberly M Hollabaugh4, Brittany N Karfonta2, Joshua A Santucci2, Benjamin O Cornwell5, Bradley N Bohnstedt6, Bin Zheng3, George L Dale7, Calin I Prodan2.   

Abstract

PURPOSE: Post-hemorrhage period after aneurysmal subarachnoid hemorrhage (aSAH) has several systemic manifestations including prothrombotic and pro-inflammatory states. Inter-relationship between these states using established/routine laboratory biomarkers and its long-term effect on clinical outcome is not well-defined.
MATERIALS AND METHODS: Retrospective analysis of prospective cohort of 44 aSAH patients. Trend of procoagulant biomarkers [coated-platelets, mean platelet volume to platelet count (MPV:PLT)] and peripheral inflammatory biomarkers [platelet-lymphocyte ratio (PLR), neutrophil-platelet ratio (NLR)] were analyzed using regression analysis. Occurrence of delayed cerebral ischemia (DCI), modified Rankin score (mRS) of 3-6 and Montreal cognitive assessment (MoCA) of <26 at 1-year defined adverse clinical outcome.
RESULTS: Patients with worse mRS and MoCA score had higher rise in coated-platelet compared to those with better scores [20.4 (IQR: 15.6, 32.9) vs. 10.95 (IQR: 6.1, 18.9), p = 0.003] and [16.9 (IQR: 13.4, 28.1) vs. 10.95 (IQR: 6.35, 18.65), p = 0.02] respectively. NLR and PLR trends showed significant initial decline followed by a gradual rise in NLR among those without DCI as compared to persistent low levels in those developing DCI (0.13 units/day vs. -0.07 units/day, p = 0.06).
CONCLUSIONS: Coated-platelet rise after aSAH is associated with adverse long-term clinical outcome. NLR and PLR trends show an early immune-depressed state after aSAH.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hemorrhagic stroke; Long-term stroke morbidity; Neutrophil-lymphocyte ratio; Platelet-lymphocyte ratio; Reactive platelets

Year:  2019        PMID: 30904732     DOI: 10.1016/j.jcrc.2019.03.003

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  6 in total

1.  Depolarization time and extracellular glutamate levels aggravate ultraearly brain injury after subarachnoid hemorrhage.

Authors:  Satoshi Murai; Tomohito Hishikawa; Yoshimasa Takeda; Yasuko Okura; Miki Fushimi; Hirokazu Kawase; Yu Takahashi; Naoya Kidani; Jun Haruma; Masafumi Hiramatsu; Kenji Sugiu; Hiroshi Morimatsu; Isao Date
Journal:  Sci Rep       Date:  2022-06-17       Impact factor: 4.996

2.  Developing new quantitative CT image markers to predict prognosis of acute ischemic stroke patients.

Authors:  Gopichandh Danala; Bappaditya Ray; Masoom Desai; Morteza Heidari; Seyedehnafiseh Mirniaharikandehei; Sai Kiran R Maryada; Bin Zheng
Journal:  J Xray Sci Technol       Date:  2022       Impact factor: 2.442

3.  Applying Quantitative Radiographic Image Markers to Predict Clinical Complications After Aneurysmal Subarachnoid Hemorrhage: A Pilot Study.

Authors:  Gopichandh Danala; Masoom Desai; Bappaditya Ray; Morteza Heidari; Sai Kiran R Maryada; Calin I Prodan; Bin Zheng
Journal:  Ann Biomed Eng       Date:  2022-02-02       Impact factor: 3.934

4.  Dynamic Change in Mean Platelet Volume and Delayed Cerebral Ischemia After Aneurysmal Subarachnoid Hemorrhage.

Authors:  Liuwei Chen; Quanbin Zhang
Journal:  Front Neurol       Date:  2020-11-30       Impact factor: 4.003

Review 5.  The Pathogenesis of Hydrocephalus Following Aneurysmal Subarachnoid Hemorrhage.

Authors:  Lu-Ting Kuo; Abel Po-Hao Huang
Journal:  Int J Mol Sci       Date:  2021-05-10       Impact factor: 5.923

Review 6.  The Role of the Blood Neutrophil-to-Lymphocyte Ratio in Aneurysmal Subarachnoid Hemorrhage.

Authors:  Lingxin Cai; Hanhai Zeng; Xiaoxiao Tan; Xinyan Wu; Cong Qian; Gao Chen
Journal:  Front Neurol       Date:  2021-06-03       Impact factor: 4.003

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.